Reportlinker Adds Therapeutics for Memory and Cognition Disord...(E OF MEMORY AND COGNITION AS TREATABLE C...),Health

TREATMENT OF CHILDREN 107

Treatment of Children (Continued) 108

KEY COMPETITIVE FACTORS 109

PRODUCT LAUNCH 109

LIFE CYCLE MANAGEMENT 109

INDUSTRY LEADERS 110

MERCK 110

TABLE 41 MERCK MEMORY AND COGNITION PIPELINE 110

ROCHE 110

TABLE 42 ROCHE MEMORY AND COGNITION PIPELINE 110

PFIZER 111

TABLE 43 PFIZER MEMORY AND COGNITION PIPELINE 111

SHIRE 111

TABLE 44 SHIRE MEMORY AND COGNITION PIPELINE 111

CEPHALON 112

TABLE 45 CEPHALON MEMORY AND COGNITION PIPELINE 112

PAYORS 112

PAYORS (CONTINUED) 113

INTERNATIONAL ASPECTS 114

TABLE 46 PER CAPITA GOVERNMENT EXPENDITURE ON HEALTHCARE BY COUNTRY, THROUGH 2006 ($ MILLIONS) 115

BIOTECHNOLOGY CLUSTERS 116

LEGISLATION AND REGULATORY ENVIRONMENT 116

VALIDATED TARGETS 116

LACK OF BIOMARKERS 116

TRANSLATIONAL MEDICINE 117

REIMBURSEMENT 118

SCHEDULING STATUS 119

MEMORY AND COGNITION AS A STAND-ALONE INDICATION 119

RELATED DEALS AND PARTNERSHIPS 119

RELATED DEALS AND PARTNERSHIPS (CONTINUED) 120

TABLE 47 RELATED DEALS AND PARTNERSHIPS, 2002-2008 121

TABLE 47 (CONTINUED) 122

TABLE 47 (CONTINUED) 123

Chapter-6: PATENT ANALYSIS

INTRODUCTION 124

TRENDS BY COUNTRY 124

TABLE 48 PATENT ANALYSIS MAJOR U.S. PATENT HOLDERS IN MEMORY/COGNITION DISORDERS 124

FIGURE 12 MAJOR PATENT HOLDERS BY ASSIGNEE (%) 125

TRENDS BY ASSIGNEE 125

TRENDS BY TECHNOLOGY 126

TABLE 49 U.S. PATENT APPLICATIONS 127

TABLE 49 (CONTINUED) 128

TABLE 49 (CONTINUED) 129

TABLE 49 (CONTINUED) 130

TABLE 49 (CONTINUED) 131

TABLE 49 (CONTINUED) 132

TABLE 49 (CONTINUED) 133

TABLE 49 (CONTINUED) 134'/>"/>